Chief Financial Officer of Cellectis, a NASDAQ-listed biotechnology company using its gene editing platform to develop life-saving cell and gene therapies, notably in oncology. Arthur oversees the finance, business development and investor relations functions. He began his career at the European Commission’s Directorate-General for Competition, controlling global pharmaceutical mergers such as the Novartis/GSK and Sanofi/Boehringer Ingelheim asset swaps, Pfizer’s acquisition of Hospira, and Teva’s acquisition of Actavis Generics. He later became Head of the Hospital Financing unit at the French Ministry of Health, where he led a team responsible for the €80bn hospital budget. Arthur graduated from ENS Ulm & Cambridge University, and holds a diploma in Immunotherapy from the Université Paris-Descartes. Arthur is also a member of the French Corps des Mines and a member of the advisory board of Life Science Cares, a not-for-profit US organization.
For a reasonably open world
